Our study identifies a new direction for the treatment of CAVD, in which miR-34c suppresses STC1 and the JNK signaling pathway, leading to the alleviation of CAVD. This evidence concerns the gene STC1 and congenital bilateral aplasia of vas deferens from CFTR mutation.